Skip to main content
ANGOAngioDynamics, Inc.Sell5.9·$12.13
ANGO · Concentration risk · 10-K extracted

AngioDynamics (ANGO) concentration risks

Updated

The most significant concentration AngioDynamics discloses is international distributors, classified MEDIUM by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Source: AngioDynamics’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗

At a glance

Disclosed-size breakdown · 1 disclosed concentration

HIGH0
MEDIUM1
LOW0
Disclosed concentrations

Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).

MEDIUMOutside partyCustomer

international distributors

“10-K Item 1A: 'International distributors accounted for approximately 75% of international revenues for the fiscal year ended May 31, 2026.'”
— SEC 10-K · filed Jul 2026
TrendMatrix Research · concentration synthesis

What these concentrations mean together

updated 2026-10-18

AngioDynamics' single disclosed concentration is a channel dependency. International distributors accounted for approximately 75% of international revenues for the fiscal year ended May 31, 2026. The filing does not quantify how much of total revenue that represents, so the share is measured only against the international portion of sales, and it should not be read as a share of the whole company. The exposure is a medium-share dependency in character. Reliance on third-party distributors means the company has less direct control over end-customer relationships, pricing, inventory levels and regulatory handling in foreign markets. A distributor that reduces orders, changes its product priorities or runs into financial or compliance trouble could move international revenue noticeably, even if the effect on the consolidated total is bounded. With no domestic customer, supplier or product concentration disclosed in the sources, there is nothing else to net against this item. The practical read is a contained, idiosyncratic channel risk confined to the international segment, and it is plainly disclosed in the filing.

For the engine’s reasoning on ANGO’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Industry peers · Medical Instruments & Supplies

Peer concentration profile

SymbolNameHIGHMEDIUMLOWTotal
ATRCAtriCure, Inc.1113
ATRAptarGroup, Inc.1102
ALGNAlign Technology, Inc.1001
AVTRAvantor, Inc.1001
ANGO●AngioDynamics, Inc.0101
AZTAAzenta, Inc.0000

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.

Concentration disclosures are extracted verbatim from SEC 10-K filings; the disclosed-size classification and the synthesis above are engine-derived. Size reflects how large each exposure is against fixed share thresholds (HIGH >50%, MEDIUM 25–50%, LOW <25% or an explicit diversification statement), not a judgment of how dangerous it is, and is not a buy/sell rating, a price target, or a view on the stock. Not a complete list of risk factors — see the full filing.

Home › Stocks › ANGO › Concentration risk